Torrent Pharmaceuticals Ltd · NSE:TORNTPHARM
Torrent Pharmaceuticals — Q2 FY2013 Earnings Presentation
21 slides from Torrent Pharmaceuticals's earnings presentation, 2012
Slide 1: Investor Presentation Q2 FY 2013
TORRENT PHARMACEUTICALS LTD. Investor Presentation Q2 FY 2013
Slide 2: Caveat
Caveat This information may contain certain forward-looking statements/ details in the current scenario, which is extremely dynamic and increasingly fraught with risks and uncertainties. Actual results, performances, achievements or sequence of events may be materially different from the views expre
Slide 3: Contents
Contents 1. Performance Highlights 2. Financials 3. Business Segments – India – International 4. Facilities – Expansion Plan
Slide 4: Q2 FY13 Highlights
Q2 FY13 Highlights • Revenues at ` 7,772 Mn vs. ` 6,849 Mn. • Revenue growth of 13%, lower on account of Brazil & Contract manufacturing operations. • Brazil operations impacted because of • strike by regulatory authority (ANVISA) affecting clearance of goods from port • lower market growth. • PBT g
Slide 5: Financials
Financials
Slide 6: Revenue Progression
Revenue Progression ` Mn P a rticu la rs Q2 Q2 1 1 -1 2 1 0 -1 1 12 - 13 11 - 12 In d ia 2710 2362 9091 8344 G w th % 15% 9% In te rn a tio n a l 4,362 3,843 14,783 11,219 G w th % 14% 32% B raz il 1161 1242 4769 3551 M ex ic o 64 38 158 61 G erm any (Heum ann) 905 938 3490 3016 US A 924 542 2162 11
Slide 7: P&L
P&L ` Mn Q2 Q2 P a r t ic u la r s 1 1 -1 2 1 0 -1 1 12 - 13 11 - 12 Revenues 7 ,7 7 2 6 ,8 4 9 2 6 ,9 5 9 2 1 ,9 7 8 C ogs 2 ,1 6 9 2 ,2 2 1 8 ,6 3 1 6 ,9 6 5 % R e v e nue s 28% 32% 32% 32% S G & A S pend 2 ,3 5 3 1 ,8 6 6 7 ,7 7 5 6 ,7 3 0 % R e v e nue s 30% 27% 29% 31% E m p lo y e e C o s t 1
Slide 8: Balance Sheet
Balance Sheet ` Mn Particulars 31-Mar-12 % 30-Sep-12 % ∆ EQUITY AND LIABILITIES Shareholders' Funds 11,938 65% 14,434 74% 2,495 Non-current liabilities 1,913 10% 1,880 10% (34) Loan Funds 4,602 25% 3,047 16% (1,555) Minority Interest 35 0% 56 0% 21 TOTAL 18,488 100% 19,416 100% 928 ASSETS Net Fixed
Slide 9: Business Segments: India
Business Segments India
Slide 10: Highlights & Growth Drivers: India
India Highlights & Growth Drivers ` Mn Q2 Q2 India 11 - 12 10 - 11 12 - 13 11 - 12 Revenues 2710 2362 9091 8344 % Growth 15% 9% • Q2 FY 13 Highlights • IPM growth 7% Covered market growth 11%, Torrent growth 12% • Acute Therapy growth (CM: 9%, Torrent 11%, Internal 13%) • Growth drivers • Consolidat
Slide 11: Business Segments: International Operations
Business Segments International Operations
Slide 12: Highlights & Growth Drivers: International Revenues
Exports Highlights & Growth Drivers ` Mn Q2 Q2 International 11-12 10-11 12 - 13 11 - 12 Revenues 4,362 3,843 14,783 11,219 %Growth 14% 32% • Q2 FY 13 Highlights • US major contributor of growth during the quarter • Growth drivers • New product introductions in key geographies of US, Brazil & Europe
Slide 13: Highlights & Growth Drivers: Brazil
Brazil Highlights & Growth Drivers ` Mn Q2 Q2 Brazil 11-12 10-11 12 - 13 11 - 12 Revenues 1161 1242 4769 3551 % Growth -7% 34% • Q2 FY 13 Highlights • Reai de-growth of 3 % with volumes de-growth 10%, New Introductions 7% • QTR (Jun- Aug) ~ Torrent growing at 6% vs. Covered Market growth of 26%. (Co
Slide 14: Highlights & Growth Drivers: USA
USA Highlights & Growth Drivers ` Mn Q2 Q2 USA 11-12 10-11 12 - 13 11 - 12 Revenues 924 542 2162 1143 % Growth 71% 89% • Q2 FY 13 Highlights • USD revenue growth of 50% • 39 ANDAs & 24 DMFs approved till date (27 actively marketed, 6 under patent & 6 under cost improvement), 25 ANDAs pending approva
Slide 15: Highlights & Growth Drivers: Germany - Heumann
Germany - Heumann Highlights & Growth Drivers ` Mn Germany Q2 Q2 11-12 10 - 11 (Heumann) 12 - 13 11 - 12 Revenues 905 938 3490 3016 % Growth -3% 16% • Q2 FY 13 Highlights • Euro revenue de growth of 4% • Growth Drivers • Heumann successful in winning tenders continuously • New Products going off pat
Slide 16: Highlights & Growth Drivers: Europe
Europe (inc UK & Romania) Highlights & Growth Drivers ` Mn Europe Q2 Q2 11-12 10-11 (inc UK & Romania) 12 - 13 11 - 12 Revenues 619 507 1931 1476 %Growth 22% 31% • Q2 FY 13 Highlights • UK & Romania major contributors of growth for the quarter • Growth Drivers • Growing product pipelines through Pro
Slide 17: Highlights & Growth Drivers: ROW
ROW Highlights & Growth Drivers ` Mn Q2 Q2 ROW 11-12 10-11 12 - 13 11 - 12 Revenues 508 408 1571 1353 % Growth 24% 16% • Q2 FY13 Highlights • Adjusted for currency movements revenue grew by 8% • Growth Drivers • Middle East/ Africa Region Delivering the growth being an upcoming market • Continuous r
Slide 18: Highlights & Growth Drivers: Mexico
Mexico Highlights & Growth Drivers ` Mn Q2 Q2 Mexico 11-12 10-11 12 - 13 11 - 12 Revenues 64 38 158 61 % Growth 69% 158% • Q2 FY 13 Highlights • Revenue growth in Mexican Peso 29% • Actively marketing 6 molecules in CNS • Field force of 35 people covering 70% of Mexican covered market. • Growth Driv
Slide 19: Facilities – Expansion Plan
Facilities – Expansion Plan
Slide 20: Facilities – Expansion Plan: Dahej SEZ
Facilities – Expansion Plan Dahej SEZ • Nature: Formulation & API Capacity Enhancement • Project Cost: ` 1000 crores • Planned capacities: 80 TPA plus 14,000 million tablets / capsules p.a. • Timelines for completion: • Phase I: Project cost of ` 600 crores, commissioning in July 2014 • Phase II: Pr
Slide 21: Thank You
Thank You
Torrent Pharmaceuticals — Q2 FY2013 Earnings Presentation on 6ix